Results
Title

FEZ1/LZTS1 protein expression in ovarian cancer.

Authors

CALIFANO, DANIELA; PIGNATA, SANDRO; PISANO, CARMELA; GREGGI, STEFANO; LAURELLI, GIUSEPPE; LOSITO, NUNZIA SIMONA; OTTAIANO, ALESSANDRO; GALLIPOLI, ADOLFO; PASQUINELLI, ROSA; DE SIMONE, VERONICA; CIROMBELLA, ROBERTO; FUSCO, ALFREDO; CHIAPPETTA, GENNARO

Abstract

The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival. On the contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma. J. Cell. Physiol. 222: 382–386, 2010. © 2009 Wiley-Liss, Inc.

Subjects

GENE expression; CHROMOSOMES; OVARIAN cancer; PROTEINS; DRUG therapy; CANCER patients

Publication

Journal of Cellular Physiology, 2010, Vol 222, Issue 2, p382

ISSN

0021-9541

Publication type

Academic Journal

DOI

10.1002/jcp.21962